|
1
|
Chin YE, Kitagawa M, Kuida K, Flavell RA
and Fu XY: Activation of the STAT signaling pathway can cause
expression of caspase 1 and apoptosis. Mol Cell Biol. 17:5328–5337.
1997.PubMed/NCBI
|
|
2
|
Kumar A, Commane M, Flickinger TW, Horvath
CM and Stark GR: Defective TNF-alpha-induced apoptosis in
STAT1-null cells due to low constitutive levels of caspases.
Science. 278:1630–1632. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chin YE, Kitagawa M, Su WC, You ZH,
Iwamoto Y and Fu XY: Cell growth arrest and induction of
cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1.
Science. 272:719–722. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Townsend PA, Scarabelli TM, Davidson SM,
Knight RA, Latchman DS and Stephanou A: STAT-1 interacts with p53
to enhance DNA damage-induced apoptosis. J Biol Chem.
279:5811–5820. 2004. View Article : Google Scholar
|
|
5
|
Stephanou A, Brar BK, Knight RA and
Latchman DS: Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and
Bcl-x promoters. Cell Death Differ. 7:329–330. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khodarev NN, Beckett M, Labay E, Darga T,
Roizman B and Weichselbaum RR: STAT1 is overexpressed in tumors
selected for radioresistance and confers protection from radiation
in transduced sensitive cells. Proc Natl Acad Sci USA.
101:1714–1719. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weichselbaum RR, Ishwaran H, Yoon T, et
al: An interferon-related gene signature for DNA damage resistance
is a predictive marker for chemotherapy and radiation for breast
cancer. Proc Natl Acad Sci USA. 105:18490–18495. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fryknäs M, Dhar S, Oberg F, et al: STAT1
signaling is associated with acquired crossresistance to
doxorubicin and radiation in myeloma cell lines. Int J Cancer.
120:189–195. 2007. View Article : Google Scholar
|
|
9
|
Roberts D, Schick J, Conway S, et al:
Identification of genes associated with platinum drug sensitivity
and resistance in human ovarian cancer cells. Br J Cancer.
92:1149–1158. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang XJ and Seto E: HATs and HDACs: from
structure, function and regulation to novel strategies for therapy
and prevention. Oncogene. 26:5310–5318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Geng H, Harvey CT, Pittsenbarger J, et al:
HDAC4 protein regulates HIF1α protein lysine acetylation and cancer
cell response to hypoxia. J Biol Chem. 286:38095–38102. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mihaylova MM, Vasquez DS, Ravnskjaer K, et
al: Class IIa histone deacetylases are hormone-activated regulators
of FOXO and mammalian glucose homeostasis. Cell. 145:607–621. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stronach EA, Alfraidi A, Rama N, et al:
HDAC4-regulated STAT1 activation mediates platinum resistance in
ovarian cancer. Cancer Res. 71:4412–4422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun Y, Chin YE, Weisiger E, et al: Cutting
edge: Negative regulation of dendritic cells through acetylation of
the nonhistone protein STAT-3. J Immunol. 182:5899–5903. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan ZL, Guan YJ, Chatterjee D and Chin
YE: Stat3 dimerization regulated by reversible acetylation of a
single lysine residue. Science. 307:269–273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanintronkul Y, Worayuthakarn R, Thasana
N, et al: Overcoming multidrug resistance in human lung cancer with
novel benzo[a]quinolizin-4-ones. Anticancer Res. 31:921–927.
2011.PubMed/NCBI
|
|
17
|
Kaewpiboon C, Lirdprapamongkol K,
Srisomsap C, et al: Studies of the in vitro cytotoxic, antioxidant,
lipase inhibitory and antimicrobial activities of selected Thai
medicinal plants. BMC Complement Altern Med. 12:2172012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim HG, Hien TT, Han EH, et al: Metformin
inhibits P-glycoprotein expression via the NF-κB pathway and CRE
transcription activity through AMPK activation. Br J Pharmacol.
162:1096–1108. 2011. View Article : Google Scholar :
|
|
19
|
Cho IR, Jeong S, Jhun BH, et al:
Activation of non-canonical NF-kappaB pathway mediated by STP-A11,
an oncoprotein of Herpesvirus saimiri. Virology. 359:37–45. 2007.
View Article : Google Scholar
|
|
20
|
Sugimoto Y, Tsukahara S, Ishikawa E and
Mitsuhashi J: Breast cancer resistance protein: molecular target
for anticancer drug resistance and
pharmacokinetics/pharmacodynamics. Cancer Sci. 96:457–465. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Young LC, Campling BG, Cole SP, Deeley RG
and Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2
in lung cancer: correlation of protein levels with drug response
and messenger RNA levels. Clin Cancer Res. 7:1798–1804.
2001.PubMed/NCBI
|
|
22
|
Ihde DC and Minna JD: Non-small cell lung
cancer. Part II: Treatment. Curr Probl Cancer. 15:105–154.
1991.PubMed/NCBI
|
|
23
|
Borst P, Evers R, Kool M and Wijnholds J:
A family of drug transporters: the multidrug resistance-associated
proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chan HS, Lu Y, Grogan TM, et al: Multidrug
resistance protein (MRP) expression in retinoblastoma correlates
with the rare failure of chemotherapy despite cyclosporine for
reversal of P-glycoprotein. Cancer Res. 57:2325–2330.
1997.PubMed/NCBI
|
|
25
|
Lee E and Lim SJ: The association of
increased lung resistance protein expression with acquired
etoposide resistance in human H460 lung cancer cell lines. Arch
Pharm Res. 29:1018–1023. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Katayama K, Noguchi K and Sugimoto Y:
FBXO15 regulates P-glycoprotein/ABCB1 expression through the
ubiquitin-proteasome pathway in cancer cells. Cancer Sci.
104:694–702. 2013. View Article : Google Scholar : PubMed/NCBI
|
